Adapalene

Evidence Level: L5

Predicted Indications: 1

Adapalene

Pharmacist Assessment Report

Adapalene: From Acne to Zinc, Elevated Plasma

One-Sentence Summary

Adapalene is a topical retinoid originally used to treat acne. The TxGNN model predicts it may be effective for elevated plasma zinc, but no clinical trials and no publications currently support this direction. The prediction rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Acne
Predicted New Indication	Zinc, elevated plasma
TxGNN Prediction Score	0.9951
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, adapalene is a topical retinoid that acts as a selective retinoic acid receptor (RAR-beta/gamma) agonist. Its efficacy in acne is established, but a mechanistic link to elevated plasma zinc has not been found.

Elevated plasma zinc is a laboratory finding or biochemical state rather than a conventional treatable disease. No known pathway connects retinoid receptor signalling to zinc homeostasis in a way that would lower plasma zinc. Topical adapalene also has low systemic exposure, which makes a systemic effect on plasma zinc even less likely.

The very high TxGNN score (0.9951) is a model output only. It may reflect a TxGNN model (deep learning) artifact, such as general retinoid–zinc associations in skin biology or shared gene-network neighbours. It should not be read as evidence of efficacy.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Twenty valid single-ingredient registrations are listed. The main five are shown below. All are topical gels, and no approved indication text is available in the data compiled for this report.

Authorization Number	Product Name	Dosage Form	Manufacturer
217787	Ticin Plus Gel	Tube of 20 gm gel	Torque Pharmaceuticals Pvt Ltd
17264	Adhibit Gel	Tube of 15 gm gel	Dupen Laboratories Pvt Ltd
5953	Aclene 0.10% Gel	Tube of 15 gm gel	Cipla Ltd
12911	Achilles 0.10% Gel	Tube of 15 gm gel	Novartis India Ltd
14480	Adene 0.1% Gel	Tube of 15 gm gel	Gary Pharmaceuticals Pvt Ltd

Safety Considerations

Disease associations flagged as contraindications in the knowledge graph (not taken from label text): photoparoxysmal response, photosensitivity disease, exfoliative dermatitis, and dermatitis.
Drug Interactions: 58 potential interactions were identified, but none has a severity level assigned. Examples include doxycycline, minocycline, tetracycline, metronidazole, prednisone, triamcinolone, budesonide, omeprazole, pantoprazole, ibuprofen, fluconazole, clopidogrel, and bupropion.

For full warnings and contraindications, please refer to the package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by a model score (Evidence Level L5). No trials or publications exist, and no plausible mechanism links a topical retinoid to lowering plasma zinc. The target is also a laboratory finding rather than a disease, and topical dosing gives low systemic exposure.

To proceed, the following is needed:

Confirmation that elevated plasma zinc is a clinically meaningful therapeutic target
Detailed mechanism of action data and any evidence linking retinoid signalling to zinc homeostasis
Preclinical or exploratory studies showing an effect on plasma zinc
Package insert warnings and contraindications from the India Pharma source, which are currently missing and block safety screening
An assessment of route compatibility, since the topical gel formulations may not achieve relevant systemic exposure
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.